357 related articles for article (PubMed ID: 19536363)
1. Insertional mutagenesis and development of malignancies induced by integrating gene delivery systems: implications for the design of safer gene-based interventions in patients.
Romano G; Marino IR; Pentimalli F; Adamo V; Giordano A
Drug News Perspect; 2009 May; 22(4):185-96. PubMed ID: 19536363
[TBL] [Abstract][Full Text] [Related]
2. Site-specific integration with phiC31 integrase for prolonged expression of therapeutic genes.
Ginsburg DS; Calos MP
Adv Genet; 2005; 54():179-87. PubMed ID: 16096012
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy progress and prospects: development of improved lentiviral and retroviral vectors--design, biosafety, and production.
Sinn PL; Sauter SL; McCray PB
Gene Ther; 2005 Jul; 12(14):1089-98. PubMed ID: 16003340
[TBL] [Abstract][Full Text] [Related]
4. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
5. Awakening gene therapy with Sleeping Beauty transposons.
Essner JJ; McIvor RS; Hackett PB
Curr Opin Pharmacol; 2005 Oct; 5(5):513-9. PubMed ID: 16084771
[TBL] [Abstract][Full Text] [Related]
6. Monitoring for potential adverse effects of prenatal gene therapy: genotoxicity analysis in vitro and on small animal models ex vivo and in vivo.
Themis M
Methods Mol Biol; 2012; 891():341-70. PubMed ID: 22648780
[TBL] [Abstract][Full Text] [Related]
7. Insertional mutagenesis in gene therapy and stem cell biology.
Baum C
Curr Opin Hematol; 2007 Jul; 14(4):337-42. PubMed ID: 17534158
[TBL] [Abstract][Full Text] [Related]
8. Phage phiC31 integrase-mediated genomic integration of the common cytokine receptor gamma chain in human T-cell lines.
Ishikawa Y; Tanaka N; Murakami K; Uchiyama T; Kumaki S; Tsuchiya S; Kugoh H; Oshimura M; Calos MP; Sugamura K
J Gene Med; 2006 May; 8(5):646-53. PubMed ID: 16508910
[TBL] [Abstract][Full Text] [Related]
9. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Hacein-Bey-Abina S; Von Kalle C; Schmidt M; McCormack MP; Wulffraat N; Leboulch P; Lim A; Osborne CS; Pawliuk R; Morillon E; Sorensen R; Forster A; Fraser P; Cohen JI; de Saint Basile G; Alexander I; Wintergerst U; Frebourg T; Aurias A; Stoppa-Lyonnet D; Romana S; Radford-Weiss I; Gross F; Valensi F; Delabesse E; Macintyre E; Sigaux F; Soulier J; Leiva LE; Wissler M; Prinz C; Rabbitts TH; Le Deist F; Fischer A; Cavazzana-Calvo M
Science; 2003 Oct; 302(5644):415-9. PubMed ID: 14564000
[TBL] [Abstract][Full Text] [Related]
10. Fragile sites are preferential targets for integrations of MLV vectors in gene therapy.
Bester AC; Schwartz M; Schmidt M; Garrigue A; Hacein-Bey-Abina S; Cavazzana-Calvo M; Ben-Porat N; Von Kalle C; Fischer A; Kerem B
Gene Ther; 2006 Jul; 13(13):1057-9. PubMed ID: 16511518
[TBL] [Abstract][Full Text] [Related]
11. Applications of Sleeping Beauty transposons for nonviral gene therapy.
Liu H; Visner GA
IUBMB Life; 2007 Jun; 59(6):374-9. PubMed ID: 17613167
[TBL] [Abstract][Full Text] [Related]
12. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
13. Insertional mutagenesis and clonal dominance: biological and statistical considerations.
Fehse B; Roeder I
Gene Ther; 2008 Jan; 15(2):143-53. PubMed ID: 17972922
[TBL] [Abstract][Full Text] [Related]
14. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
15. Transposable elements for transgenesis and insertional mutagenesis in vertebrates: a contemporary review of experimental strategies.
Ivics Z; Izsvák Z
Methods Mol Biol; 2004; 260():255-76. PubMed ID: 15020812
[TBL] [Abstract][Full Text] [Related]
16. DNA transposons for modification of human primary T lymphocytes.
Huang X; Wilber A; McIvor RS; Zhou X
Methods Mol Biol; 2009; 506():115-26. PubMed ID: 19110623
[TBL] [Abstract][Full Text] [Related]
17. A direct comparison of two nonviral gene therapy vectors for somatic integration: in vivo evaluation of the bacteriophage integrase phiC31 and the Sleeping Beauty transposase.
Ehrhardt A; Xu H; Huang Z; Engler JA; Kay MA
Mol Ther; 2005 May; 11(5):695-706. PubMed ID: 15851008
[TBL] [Abstract][Full Text] [Related]
18. Retroviral vectors: new applications for an old tool.
Barquinero J; Eixarch H; Pérez-Melgosa M
Gene Ther; 2004 Oct; 11 Suppl 1():S3-9. PubMed ID: 15454951
[TBL] [Abstract][Full Text] [Related]
19. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy.
Romano G
ISRN Oncol; 2012; 2012():616310. PubMed ID: 23209944
[TBL] [Abstract][Full Text] [Related]
20. Transposon-based mutagenesis generates diverse adeno-associated viral libraries with novel gene delivery properties.
Koerber JT; Schaffer DV
Methods Mol Biol; 2008; 434():161-70. PubMed ID: 18470644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
